Distinct genomic landscapes of ALK-positive and ALK-negative systemic anaplastic large cell lymphomas: clinical impacts and translational significance

Abstract Background Anaplastic large cell lymphoma (ALCL) comprises biologically distinct entities based on anaplastic lymphoma kinase (ALK) expression, itself a reflection of ALK rearrangement status. Even as genetic alterations have been used to subtype ALCL, the outcomes remain heterogeneous, indicating that current genetic subgrouping does not fully stratify risk ALK-negative ALCL. Methods 149 ALCL biopsy samples (ALK-positive, n = 75; ALK-negative, n = 74) with accompanying clinical data were accrued to identify genomic factors that impact on outcomes. Genetic variants, copy number variants and gene expression profiles were assessed. Results ALK‑negative patients showed inferior overall survival (OS) compared with ALK-positive patients ( p < 0.05). ALK‑negative ALCL that harbored TP53 mutations had the poorest overall and progression-free survival compared to ALK-positive or ALK-negative TP53 ‑wild type cases ( p < 0.05). Mutational burden and copy number variation burden were highest in ALK‑negative, TP53 -mutated cases compared with either of the other groups ( p < 0.05). Finally, we identified a three-gene mutation signature comprised of TP53 , KMT2D and TET2 that significantly stratified overall survival risk across the subtypes. Conclusions Our findings define the differing genomic landscapes underlying ALK-positive and ALK-negative ALCL and point to potential new approaches for risk assessment and targeted therapy strategies.

Authors

Publication Details

Journal
Biomarker Research
Published
2026-11-15
DOI
https://doi.org/10.1186/s40364-026-01039-2
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Distinct genomic landscapes of ALK-positive and ALK-negative systemic anaplastic large cell lymphomas: clinical impacts and translational significance

Jamilla Li, Payal Sojitra, Dennis Owusu, Ilja Kalashnikov et al.
Biomarker Research
Lymphoma Diagnosis and Treatment
article

Distinct genomic landscapes of ALK-positive and ALK-negative systemic anaplastic large cell lymphomas: clinical impacts and translational significance

Jamilla Li, Payal Sojitra, Dennis Owusu, Ilja Kalashnikov, Anne Ortved Gang, Govind Bhagat, Devang Thakkar, Chad M. McCall, Eric D. Hsi, Clay Parker, Lanie E. Happ, Abner Louissaint, Elizabeth Thacker, Ridas Juskevicius, Yok‐Lam Kwong, Kikkeri N. Naresh, Jason Yongsheng Chan, Magdalena Czader, Sarah Lynn Ondrejka, Jennifer R. Shingleton, Rex K.H. Au-Yeung, Rohit Gulati, Amy Chadburn, Veronica S. Russell, David L. Jaye, Raju K. Pillai, Amir Behdad, Juan Pablo Alderuccio, Jean Louise Koff, Mette Ølgod Pedersen, Sandeep S. Davé, Mary Ann Thompson, Jie Xu, Andrew Evans, Jennifer Rose Chapman-Fredricks, Leonardo P. A. Biral, Cassandra Love, Catalina Amador, Chee Leong Cheng, Yuri Fedoriw, Sirpa Leppä, Eric Tse, Alvin Ip, Shaoying Li, William Choi, Lin Wang, Carlos Galvez, Harry Gill, Matthew McKinney, Carmen Lee
article en

Abstract

Abstract Background Anaplastic large cell lymphoma (ALCL) comprises biologically distinct entities based on anaplastic lymphoma kinase (ALK) expression, itself a reflection of ALK rearrangement status. Even as genetic alterations have been used to subtype ALCL, the outcomes remain heterogeneous, indicating that current genetic subgrouping does not fully stratify risk ALK-negative ALCL. Methods 149 ALCL biopsy samples (ALK-positive, n = 75; ALK-negative, n = 74) with accompanying clinical data were accrued to identify genomic factors that impact on outcomes. Genetic variants, copy number variants and gene expression profiles were assessed. Results ALK‑negative patients showed inferior overall survival (OS) compared with ALK-positive patients ( p < 0.05). ALK‑negative ALCL that harbored TP53 mutations had the poorest overall and progression-free survival compared to ALK-positive or ALK-negative TP53 ‑wild type cases ( p < 0.05). Mutational burden and copy number variation burden were highest in ALK‑negative, TP53 -mutated cases compared with either of the other groups ( p < 0.05). Finally, we identified a three-gene mutation signature comprised of TP53 , KMT2D and TET2 that significantly stratified overall survival risk across the subtypes. Conclusions Our findings define the differing genomic landscapes underlying ALK-positive and ALK-negative ALCL and point to potential new approaches for risk assessment and targeted therapy strategies.

Biomarker ResearchVol. 14(1)
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon